Results 191 to 200 of about 89,075 (280)

A Clinical Guidance for the Management of Patients With Hepatoid Adenocarcinoma and A Case Series

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Hepatoid adenocarcinoma (HAC) is a rare extrahepatic tumor of non‐germ cell origin that morphologically resembles hepatocellular carcinoma (HCC). HAC has a propensity to metastasize to the liver and therefore may be mistaken for HCC. There is a lack of standardized treatment protocols, and further studies are needed to evaluate the benefit of ...
Christina Liava, Sudhakar Venkatesh, Michael S. Torbenson, Patrick S. Kamath, Moira Hilscher   +4 more
wiley   +1 more source

Prognostic Significance of Combined PD-L1 Expression and Chemotherapeutic Status in Cholangiocarcinoma Patients. [PDF]

Cancer Diagn Progn
Padthaisong S, Thanee M, Dokduang H, O'Connor T, Loilome W.   +4 more
europepmc   +1 more source

Prognostic predictive value of sarcopenia and systemic immune-inflammatory index in patients after radical surgery for distal cholangiocarcinoma. [PDF]

Sci Rep
Ma Z, Lin Y, Zhang B, Yue P, Li B, Meng W.   +5 more
europepmc   +1 more source

Crosstalk Between Intratumoral Microbes and Tumor Immunity: Implications for Tumor Therapy

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Background Emerging studies indicate that microbes are present in tumor cells and immune cells. Intratumoral microbiota (ITM) constitute an important component of the tumor immune microenvironment (TIME) and have an important impact on tumor progression and treatment. Objective Through the general elaboration of ITM represented by bacteria and
Fengxue Li, Lili Qiao, Xinquan Liang, Yingying Zhang, Ning Liang, Jian Xie, Guodong Deng, Yuying Hao, Pingping Hu, Xue Wu, Fangjie Ding, Can Feng, Yiming Mu, Jiandong Zhang   +13 more
wiley   +1 more source

Clinical Relevance of Ratios Derived from Routine Blood-Based Biomarkers in Cholangiocarcinoma: A Retrospective Cohort Study. [PDF]

Medicina (Kaunas)
Ventuneac AD, Seicean A, Al Hajjar N, Chira R, Ciocan A, Ichim VA, Bolboacă SD.   +6 more
europepmc   +1 more source

Surufatinib plus anti‐PD‐1/PD‐L1 antibody as second‐line therapy for advanced biliary tract cancer: A single‐centre investigator‐initiated trial

Clinical and Translational Discovery, Volume 6, Issue 1, February 2026.
Abstract Objective To explore the efficacy and safety of surufatinib in combination with anti‐PD‐1/PD‐L1 antibodies (with or without chemotherapy) in patients with advanced BTC after failure of first‐line treatment. Methods 24 patients with advanced BTC who failed first‐line treatment were admitted to our centre from March 2023 to August 2024 and ...
Xinni Chen, Feng Wang, Yuan Cheng, Mengran Cao, Kuimin Mei, Xiaoyuan Chu, Fang Dai, Xinlei Gong   +7 more
wiley   +1 more source

Correction: Coexistence of bullous pemphigoid, intrahepatic cholangiocarcinoma, and alopecia areata: a case report of multifactorial autoimmunity in a surgical context. [PDF]

Front Immunol
Li S, Wang Y, Yang D.
europepmc   +1 more source

Proximal cholangiocarcinomas

Journal of British Surgery, 1988
openaire   +2 more sources

CEACAM6 silencing suppresses tumour growth and sensitises cholangiocarcinoma to cisplatin

Clinical and Translational Discovery, Volume 6, Issue 1, February 2026.
CEACAM6 has the potential to become a novel and independent prognostic biomarker in cholangiocarcinoma (CCA). Silencing CEACAM6 can inhibit CCA tumour growth and significantly enhance the chemosensitivity to cisplatin. This chemo‐sensitising effect is mediated through the disruption of ribosome biogenesis and impairment of DNA damage repair.
Shi‐Jia Dai, Jiang‐Qi Tan, Jia‐Qi Guo, Ya‐Nan Zhou, Teng Huang, Hao‐Lin Jiang, Yang Liu, Li‐Wei Dong, Zhen‐Gang Yuan   +8 more
wiley   +1 more source

Amino acid metabolic reprogramming: future prospects for cholangiocarcinoma therapy. [PDF]

Cell Death Discov
Hua S, Fei F, Li J, Liu Y, Gao Y, Wang X, Dong X, Liu Q, Yang J.   +8 more
europepmc   +1 more source